New paper on data-driven targeted screening in Alzheimer's disease clinical trials!

Our recent work on targeted screening in clinical trials has been published in Frontiers. The paper, “Targeted screening for Alzheimer’s disease clinical trials using data-driven disease progression models”, trains an event-based model (EBM) on ADNI data to use to stage the cohort of a completed double-blind clinical trial of donepezil in people with amnestic mild cognitive impairment. In short, one of the identified subgroups with more severe cognitive impairment exhibited a clearer treatment response than the full cohort.

Along with work we recently presented at AD/PD™ and will be presenting at AAIC (come say hi!), this forms an increasing body of work that we’ve produced to show the utility of disease progression modelling in screening for clinical trials, allowing for a reduction in heterogeneity with the hopes of improving sensitivity (and removing potential confounders) in clinical trials.

If you’d like to hear more, or use our models in the analysis of your own data, please get in touch with lead author Neil Oxtoby or Cameron Shand.

• DOI: To add when finalized!